

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JC20 Rec'd PCT/PTO 29 APR 2002

In re Application of:

MARTIN, Thomas

International Application No. EP00/08899

Serial No. 10/070,279

International Filing Date: 12 September 2000 (12.09.00)

Filed: March 6, 2002

For: TRYPTASE INHIBITORS

TRANSMITTAL LETTER

The Commissioner for Patents  
Washington, D.C. 20231

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark  
Office is the following:

- 1) Transmittal Letter;
- 2) Submission of Information Disclosure Statement;
- 3) PTO Form 1449 with 5 references.

Respectfully submitted,


NATH &amp; ASSOCIATES PLLC

By: 

Gary M. Nath  
Registration No. 26,965  
Todd L. Juneau  
Registration No. 40,669  
Customer No. 20529

Date: Apr 24, 2002  
NATH & ASSOCIATES PLLC  
1030 15<sup>TH</sup> Street, NW - 6<sup>th</sup> Floor  
Washington, D.C. 20005  
GMN/TLJ/dd:IDS.trans

RECEIVED  
SEP 09 2002  
TECH CENTER 1600/2900



12/10/02  
SW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

MARTIN, Thomas

International Application No. PCT/EP00/08899

Serial No. 10/070,279 ✓

International Filing Date: 12 September 2000 (12.09.00)

Filed: March 6, 2002 ✓

For: TRYPTASE INHIBITORS ✓

INFORMATION DISCLOSURE STATEMENTCommissioner of Patents  
Washington, D.C. 20231

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. §1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]

- [ X ] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. §1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- [ ] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311.

The enclosed statement is accompanied by [check one]:

- [ ] i. a certification in part (e) below as specified in 37 C.F.R. §1.97(e), or
- [ ] ii. a check in the amount required by 37 C.F.R. §1.17(p).
- [ ] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311, but before payment of the issue fee.
- [ ] Certification report(e) below; and
- [ ] a check in the amount as required by §1.17(p).
- [ ] d. The enclosed statement is being filed pursuant to 37 C.F.R. §1.97(i), for placement in the file.
- [ ] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

☐ I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

☐ I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

☐ Appropriate certification is attached.

☒ f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

☒ g. Copies of the documents are attached herewith with a completed Form PTO-1449.

or

☐ Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,  
**NATH & ASSOCIATES**

By: 

Gary M. Nath  
Registration No. 26,965  
Todd L. Juneau  
Registration No. 40,669  
Customer No. 20529

Date: Apr 25, 2002

NATH & ASSOCIATES  
1030 15<sup>th</sup> Street, N.W., 6<sup>th</sup> Floor  
Washington, D.C. 20005  
Tel. (202) 775-8383  
Fax. (202) 775-8396  
GMN/TLJ/dd (IDS.revisedTLJ04.08.02)

<b>FORM PTO-1449</b>  <b><u>INFORMATION DISCLOSURE CITATION</u></b>				Atty Docket 24903		Serial No. 10/070,279	
				Applicant Thomas MARTIN			
				Filing Date March 6, 2002		Group Art Unit not yet assigned	

U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub-Class	Translation
	AL	98/04537	5.02.98	WO			N/A
	AM	96/09297	28.03.96	WO			N/A
	AN	95/32945	07.12.95	WO			N/A
	AO	99/40083	12.08.99	WO			YES
	AP						

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR		Rice, K.D., et al., "Inhibitors of Tryptase for the Treatment of Mast Cell-Mediated Diseases", Current Pharmaceutical Design, V.4, no. 5, pp. 381-396, (1998).
	AS		
	AT		

Examiner	Date Considered
----------	-----------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

SEP 09 2002

TECH CENTER 1600/2900